Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3)

Molecular Pharmacology

Volumn 69, Issue 5, 2006, Pages 1542-1553

  Hu, Huankai ^a   Endres, Christopher J ^c   Chang, Cheng ^b   Umapathy, Nagavedi S ^a   Lee, Eun Woo ^c   Fei, You Jun ^a   Itagaki, Shirou ^a   Swaan, Peter W ^b   Ganapathy, Vadivel ^a   Unadkat, Jashvant D ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLADENOSINE; 3 DEAZAURIDINE; 3' DEOXYURIDINE; 5' DEOXYADENOSINE; ADENOSINE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; CYTIDINE; DEOXYADENOSINE; DEOXYGUANOSINE; DEOXYINOSINE; DEOXYURIDINE; DOXIFLURIDINE; FLUOROURIDINE; GEMCITABINE; GUANOSINE; HYDROXYL GROUP; IDOXURIDINE; INOSINE; NUCLEIC ACID BASE; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRANSPORTER; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RIBAVIRIN; RIBOSE; SODIUM ION; THYMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ELECTRICITY; ELECTROPHYSIOLOGY; FEMALE; FORCE; HILL REACTION; HYDROGEN BOND; HYDROPHOBICITY; HYPERPOLARIZATION; KINETICS; MEMBRANE POTENTIAL; MICROELECTRODE; MOLECULAR MODEL; NONHUMAN; OOCYTE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SLOW INWARD CURRENT; STATISTICAL SIGNIFICANCE; STEADY STATE; STEREOSPECIFICITY; VOLTAGE CLAMP; XENOPUS LAEVIS;

ALGORITHMS; ANIMALS; DEOXYCYTIDINE; ELECTROPHYSIOLOGY; FEMALE; HUMANS; KINETICS; MEMBRANE POTENTIALS; MEMBRANE TRANSPORT PROTEINS; NUCLEOSIDES; OOCYTES; PURINES; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; XENOPUS LAEVIS;

EID: 33645828207     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.018945     Document Type: Article

References (35)

1. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, and Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflueg Arch Eur J Physiol 447:735-743.
2. Bergstrom CA, Strafford M, Lazorova L, Avdeef A, Luthman K, and Artursson P (2003) Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558-570.
3. +/hexose cotransporter (STP1) from Arabidopsis thaliana expressed in Xenopus oocytes. J Biol Chem 269:20417-20424.
4. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, and Pastor-Anglada M (2004) Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 9:993-1002.
5. Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD, and Unadkat JD (2004) Molecular requirements of the human nucleoside transporters hCNT1, hCNT2 and hENT1. Mol Pharmacol 65:558-570.
6. Gray JH, Owen RP, and Giacomini KM (2004) The concentrative nucleoside transporter family, SLC28. Pflueg Arch Eur J Physiol 447:728-734.
7. +-dependent nucleoside transporter in microglia. J Pharmacol Exp Ther 292:366-374.
8. Horwitz JP, Massova I, Wiese TE, Besler BH, and Corbett TH (1994) Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03. J Med Chem 37:781-786.
9. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, and Sadee W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-4301.
10. Jarvis SM, Thorn JA, and Glue P (1998) Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 123:1587-1592.
11. Jones G, Willett P, and Glen RC (1995) A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des 9:532-549.
12. Kong W, Engel K, and Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5:63-84.
13. Kroemer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, and Kornhuber J (1998) Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site. J Med Chem 41:393-400.
14. Lai Y, Lee EW, Ton CC, Vijay S, Zhang H, and Unadkat JD (2005) Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. Am J Physiol 288:C39-C45.
15. Lai Y, Tse CM, and Unadkat JD (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279:4490-4497.
16. +/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. J Biol Chem 279:8999-9007.
17. +/glucose cotransporter. Proc Natl Acad Sci USA 90:5767-5771.
18. Lum PY, Ngo LY, Bakken AH, and Unadkat JD (2000) Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. Cancer Chemother Pharmacol 45:273-278.
19. +/oligopeptide cotransporter hPEPT1 transports differently-charged dipeptides with identical electrogenic properties. Biochim Biophys Acta 1284:125-128.
20. +-coupled oligopeptide transporter hPEPT1. J Biol Chem 271:5430-5437.
21. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, and Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-4357.
22. Mangravite LM, Badagnani I, and Giacomini KM (2003) Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 479:269-281.
23. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, and Pavlik PA (1993) A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Des 7:83-102.
24. Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ, and Pastor-Anglada M (2001) Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59:1542-1548.
25. +/glucose cotransporter. J Biol Chem 270:27099-27105.
26. +/glucose cotransporter: II. A transport model under nonrapid equilibrium conditions. J Membr Biol 125:63-79.
27. +-nucleoside purine (N1) transporter. Pharm Res (NY) 15:950-952.
28. +-nucleoside transporters. Cancer Chemother Pharmacol 46:394-402.
29. +- nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927.
30. Schaal W, Karlsson A, Ahlsen G, Lindberg J, Andersson HO, Danielson UH, Classon B, Unge T, Samuelsson B, Hulten J, et al. (2001) Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J Med Chem 44:155-169.
31. +/ nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biol Chem 280:25436-25449.
32. Swaan PW, Szoka FC Jr, and Oie S (1997) Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study. J Comput Aided Mol Des 11:581-588.
33. Toan SV, To KK, Leung GP, de Souza MO, Ward JL, and Tse CM (2003) Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. Pflueg Arch Eur J Physiol 447:195-204.
34. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 64:1512-1520.
35. Zhang JL, Simeonowa I, Wang Y, and Sebald W (2002) The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. J Mol Biol 315:399-407.